Enclomiphene
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Enclomiphene
- Accession Number
- DB06735
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Enclomiphene (DB06735)
- Weight
- Average: 405.97
Monoisotopic: 405.1859422 - Chemical Formula
- C26H28ClNO
- Synonyms
- Enclomifene
- Enclomifeno
- Enclomifenum
- Enclomiphene
- trans-Clomifene
- trans-Clomiphene
- External IDs
- RMI 16,289
- RMI-16,289
- RMI-16289
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbatacept The metabolism of Enclomiphene can be increased when combined with Abatacept. Abiraterone The metabolism of Enclomiphene can be decreased when combined with Abiraterone. Acebutolol The metabolism of Enclomiphene can be decreased when combined with Acebutolol. Acetaminophen The metabolism of Enclomiphene can be decreased when combined with Acetaminophen. Adalimumab The metabolism of Enclomiphene can be increased when combined with Adalimumab. Almotriptan The metabolism of Enclomiphene can be decreased when combined with Almotriptan. Alogliptin The metabolism of Enclomiphene can be decreased when combined with Alogliptin. Aminophenazone The metabolism of Enclomiphene can be decreased when combined with Aminophenazone. Amiodarone The metabolism of Amiodarone can be decreased when combined with Enclomiphene. Amitriptyline The metabolism of Enclomiphene can be decreased when combined with Amitriptyline. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Enclomiphene citrate J303A6U9Y6 7599-79-3 PYTMYKVIJXPNBD-BTKVJIOYSA-N - International/Other Brands
- Androxal
Categories
- Drug Categories
- Benzene Derivatives
- Benzylidene Compounds
- Clomiphene
- Cytochrome P-450 CYP2D6 Substrates
- Cytochrome P-450 Substrates
- Estrogen Antagonists
- Estrogen Receptor Modulators
- Fertility Agents
- Fertility Agents, Female
- Hormone Antagonists
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Reproductive Control Agents
- Selective Estrogen Receptor Modulators
- Stilbenes
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Stilbenes
- Sub Class
- Not Available
- Direct Parent
- Stilbenes
- Alternative Parents
- Diphenylmethanes / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Trialkylamines / Vinyl chlorides / Chloroalkenes / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
- Substituents
- Alkyl aryl ether / Amine / Aromatic homomonocyclic compound / Benzenoid / Chloroalkene / Diphenylmethane / Ether / Haloalkene / Hydrocarbon derivative / Monocyclic benzene moiety
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- R6D2UI4FLS
- CAS number
- 15690-57-0
- InChI Key
- GKIRPKYJQBWNGO-OCEACIFDSA-N
- InChI
- InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25+
- IUPAC Name
- (2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}ethyl)diethylamine
- SMILES
- CCN(CC)CCOC1=CC=C(C=C1)C(=C(\Cl)C1=CC=CC=C1)\C1=CC=CC=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 1548953
- PubChem Substance
- 347827784
- ChemSpider
- 1265967
- BindingDB
- 55354
- ChEMBL
- CHEMBL954
- ZINC
- ZINC000001530601
- PharmGKB
- PA449046
- PDBe Ligand
- 53Q
- Wikipedia
- Enclomifene
- PDB Entries
- 5cqj / 6vpf
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Not Available Effect of Treatment on Bone Mineral Density 1 3 Completed Treatment Secondary Hypogonadotrophic hypogonadism 6 2 Completed Treatment Acquired Hypogonadotropic Hypogonadism / BMI >30 kg/m2 1 2 Completed Treatment Hypogonadism / Low Testosterone 1 2 Completed Treatment Secondary Hypogonadotrophic hypogonadism 3 2 Completed Treatment Secondary Hypogonadotrophic hypogonadism / Type 2 Diabetes Mellitus 1 2, 3 Withdrawn Treatment Infertility 1 1 Completed Diagnostic Secondary Hypogonadotrophic hypogonadism 2 1 Completed Treatment Bioequivalence 1 1 Completed Treatment Drug Drug Interaction (DDI) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000414 mg/mL ALOGPS logP 6.08 ALOGPS logP 6.47 ChemAxon logS -6 ALOGPS pKa (Strongest Basic) 9.31 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 12.47 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 133.76 m3·mol-1 ChemAxon Polarizability 46.93 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0udi-3791200000-10b7e9d8e7060a9b1b01
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Ghobadi C, Gregory A, Crewe HK, Rostami-Hodjegan A, Lennard MS: CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet. 2008;23(2):101-5. [PubMed:18445989]
Drug created on August 30, 2010 13:38 / Updated on October 19, 2020 02:19
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates